In addition, hERG1 behaved as a positive biomarker of therapy response, since those patients whose tumor was hERG1 positive and were treated with chemotherapy plus a hERG1 blocker (for the treatment of co-morbidities) had a longer survival compared to patients not treated with a hERG1 blocker. This evidence concerns the gene KCNH2 and neoplasm.